{
    "nct_id": "NCT03456700",
    "official_title": "Phase II Trial to Evaluate the Efficacy of Auranofin and Sirolimus in Serous Ovarian Cancer Patients With Recurrent Disease",
    "inclusion_criteria": "* Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1\n* Ovarian, Fallopian Tube or Primary Peritoneal cancer of serous histology\n* Incurable cancer\n* Willingness to provide paraffin-embedded tissue blocks of ovarian cancer\n* Measurable disease\n* Obtained =< 14 days prior to registration: Absolute neutrophil count (ANC) >= 1500 uL\n* Obtained =< 14 days prior to registration: Platelet (PLT) >= 100,000 uL\n* Obtained =< 14 days prior to registration: Hemoglobin (Hgb) >= 9 g/dL\n* Obtained =< 14 days prior to registration: Total bilirubin =< 1.5 x upper limit of normal (ULN) or direct bilirubin =< ULN\n* Obtained =< 14 days prior to registration: Serum glutamic-oxaloacetic transaminase (SGOT) (aspartate aminotransferase [AST]) and serum glutamate pyruvate transaminase (SGPT) (alanine aminotransferase [ALT]) =< 3 x ULN or SGOT (AST) and SGPT (ALT) =< 5 x ULN is acceptable if liver has tumor involvement\n* Obtained =< 14 days prior to registration: Creatinine =< 1.5 x ULN\n* Obtained =< 14 days prior to registration: Fasting serum glucose =< 1.5 x ULN\n* Obtained =< 14 days prior to registration: Total cholesterol =< 1.5 x ULN\n* Obtained =< 14 days prior to registration: Triglycerides =< 1.5 x ULN\n* Life expectancy >= 12 weeks\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Platinum-sensitive disease (exceptions allowed: patient has had a hypersensitivity reaction to platinum or the treating oncologist thinks that further platinum therapy is not in the patient?s best interest)\n* Morbidities or concurrent major illness (for example, bowel obstruction or a second active malignancy) that, in the opinion of the treating healthcare provider, would make participation in the trial problematic\n* Leptomeningeal disease or uncontrolled brain metastasis\n* Failure to recover from acute, reversible effects of prior therapy regardless of interval since last treatment\n\n  * NOTE: Patients can have peripheral (sensory) neuropathy\n* History of hypertriglyceridemia or hypercholesterolemia and currently on medication(s)\n* Use of St. John?s wort =< 7 days prior to registration\n* Unable to discontinue use of a strong CYP3A4 inhibitor",
    "miscellaneous_criteria": ""
}